Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Sulfatinib (HMPL-012) is a novel oral small molecule that selectively inhibits vascular
endothelial growth factor receptors (VEGFR) 1, 2, and 3 and inhibits FGFR kinase activity has
demonstrated potent inhibitory effects on multiple human tumor xenografts. This
first-in-human study is conducted to assess the maximum tolerated dose (MTD) and recommended
dose for phase II ,to evaluate the pharmacokinetics , safety and preliminary anti-tumor
activity of HMPL-012 at single doses and multiple doses .